Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > "Ventripoint has emerged as a standout, globally,🚀💰
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Jan 20, 2024 2:34pm
116 Views
Post# 35837468

RE:"Ventripoint has emerged as a standout, globally,🚀💰

RE:"Ventripoint has emerged as a standout, globally,🚀💰good comment AGS and Really impressive on linkedin..Joe Mullins applauded her post!
great weeks to come with several exciting news $$$
 Alvira posted on linkedin..Joe Mullins applauded her post!
 
10
 
@AGS @Samburns sammy do you have a screenshot or link? Nice share
 
0
 
@AGS For those who do not know Joe Mullings he is a LION. Check out this quote from him I posted last summer on this board: “If you look at AI as it goes to optimization of current workflow, that’s where your low-hanging fruit is. And I think the device companies that are going to be billion-dollar exits are going to be more focused on: ‘What’s existing today? How do I optimize it? How do I address the labor issue? How do I make the clinicians job a little easier, drop their cognitive load? And how do I work with what’s existing already in the ecosystem?’ Because that’s where Medtronic and J&J and Stryker and Edwards will spend billions of dollars in acquisitions that protect the moat they already have — [and] supercharges it.” Joe Mullings CEO of The Mullings Group
 
9
 
@nicolaosK ^ Spend Billions...this means 2 or more Billion. Thanks for the share @AGS
 
8
 
@AGS Now does this not get your juices flowing as a shareholder in VPT? Ascend VMS
 
8
 
@nicolaosK As the days go by this will become easier and easier to hold for the long haul
Really impressive on linkedin..Joe Mullins applauded her post !Bravo Alvira 

• 3e et +Chairman & CEO / MedTech's Top Search Consultant /The Mullings Group Companies/Board Member/Angel Investor/Keynote Speaker

Nicely done Alvira





 
As we move into commercialization of our VMS+ technology in 2024, Ventripoint is getting noticed.

Canada Health Watch, read by key health care administrators and care-givers, states "Ventripoint has emerged as a standout, with some truly breakthrough tech that uses AI to improve patient care, and brings with it the potential to lower health system costs.. . "

Getting such attention is a testament to the effectiveness of our technology, the team that built it and, I believe, a taste of what's ahead.

Read the full article here:
 
 
 
 

 

 
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities